Home › Compare › SZENF vs ABBV
SZENF yields 285.71% · ABBV yields 3.06%● Live data
📍 SZENF pulled ahead of the other in Year 1
Combined, SZENF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SZENF + ABBV for your $10,000?
Seazen Group Limited, together with its subsidiaries, engages in the investment, development, and sale of properties in the People's Republic of China. It primarily develops and sells residential properties and mixed-use complexes, as well as provides commercial property management and other services. As of December 31, 2021, the company had total land bank of approximately 138 million square meters. It also provides asset operation and management, information technology, and children entertainment, and cinema management services. In addition, the company offers securities and future brokerage, and money lending services, as well as dealing and advising services of securities. Further, it provides architecture designing services; and designs, manufactures, and sells auto parts. The company was formerly known as Future Land Development Holdings Limited and changed its name to Seazen Group Limited in November 2019. The company was founded in 1996 and is headquartered in Shanghai, the People's Republic of China. Seazen Group Limited is a subsidiary of Wealth Zone Hong Kong Investments Limited.
Full SZENF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.